Retraction: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
Expression of Concern: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
- 1Applied Biology, Inc. Irvine, CA, United States
- 2Department of Endocrinology, Corpometria Institute, Brasilia, Brazil
- 3Dermatology Department, Ramón y Cajal Hospital, Madrid, Spain
- 4Department of Dermatology and Venereology, University Hospital Center “Sestre Milosrdnice”, Zagreb, Croatia
- 5Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY, United States
- 6Sinclair Dermatology, Melbourne, VIC, Australia
- 7Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL, United States
- 8School of Medicine, European University Cyprus, Nicosia, Cyprus
- 9Intensive Care Unit, Samel Hospital, Manaus, Brazil
- 10Hospital da Brigada Militar, Porto Alegre, Brazil
- 11Department of Dermatology, Alpert Medical School of Brown University, Providence, RI, United States
Citation: McCoy J, Goren A, Cadegiani FA, Vaño-Galván S, Kovacevic M, Situm M, Shapiro J, Sinclair R, Tosti A, Stanimirovic A, Fonseca D, Dorner E, Onety DC, Zimerman RA and Wambier CG (2021) Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial. Front. Med. 8:668698. doi: 10.3389/fmed.2021.668698
Received: 17 February 2021; Accepted: 11 June 2021;
Published: 19 July 2021; Retracted: 10 June 2022.
Edited by:
Zisis Kozlakidis, International Agency For Research on Cancer (IARC), FranceReviewed by:
Chao Ren, First Hospital Affiliated to the Chinese PLA General Hospital, ChinaOlufemi Babalola, ECWA Bingham University, Nigeria